QuidelOrtho (QDEL) AI Stock Analysis

• Market Cap: $2.02B
• Dividend Yield: N/A
• Average Volume (3M): 1.30M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.17
• Revenue Growth: -3.00%
• EPS Growth: 76.48%
• Country: US
• Employees: 6,600
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.12
• Shares Outstanding: 67,900,470
• 10 Day Avg. Volume: 1,107,488
• 30 Day Avg. Volume: 1,300,130
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.99
• Price to Sales (P/S): 1.06
• P/FCF Ratio: -26.38
• Enterprise Value/Market Cap: 2.27
• Enterprise Value/Revenue: 1.68
• Enterprise Value/Gross Profit: 3.68
• Enterprise Value/Ebitda: 20.64
• 1Y Price Target: $39.50
• Price Target Upside: 32.55% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 8

• Rating: 52 Neutral
• Price Target: $29.00 ▼(-2.68% Downside)

QuidelOrtho's stock score is primarily impacted by its financial performance, which shows significant challenges with declining revenues and profitability. Technical analysis indicates potential stability, but valuation metrics are unattractive due to negative earnings. The earnings call highlighted growth in specific segments, but overall challenges remain.

Positive Factors

Improved Profitability Metrics

The improvement in EBITDA margin indicates enhanced operational efficiency, which can lead to better cash flow and financial health, supporting long-term growth.

Strong International Growth

Strong international growth diversifies revenue streams and reduces reliance on any single market, enhancing resilience against regional economic fluctuations.

Successful ERP System Conversion

The successful ERP conversion can streamline operations and reduce future integration costs, improving efficiency and supporting scalability.

Negative Factors

Decline in North America Revenue

A decline in North America revenue suggests challenges in a key market, which could impact overall revenue growth and market position if not addressed.

Decreased COVID Revenue

The significant drop in COVID-related revenue reflects reduced demand, impacting short-term revenue and necessitating a shift in focus to other growth areas.

Challenges in Donor Screening Business

The decline in the Donor Screening segment indicates strategic challenges, requiring reallocation of resources to more promising areas to maintain growth.

QuidelOrtho Business Overview & Revenue Model

Company Description

QuidelOrtho Corporation (QDEL) is a leading provider of diagnostic solutions, primarily focused on infectious diseases, reproductive health, and acute care testing. The company operates in the healthcare sector, specializing in the development, manufacturing, and marketing of rapid diagnostic tests and related technologies. QuidelOrtho's core products include point-of-care testing devices, molecular diagnostics, and immunoassays, which are designed to provide rapid and accurate results for healthcare professionals and patients.

How the Company Makes Money

QuidelOrtho generates revenue through the sale of its diagnostic products and services. The company primarily earns money from its extensive portfolio of rapid diagnostic tests, which are used in various clinical settings, including hospitals, laboratories, and physician offices. Key revenue streams include sales of immunoassay and molecular diagnostic products, as well as related consumables and accessories. Additionally, QuidelOrtho benefits from strategic partnerships with healthcare providers, distributors, and research institutions that enhance its market reach and product offerings. The company's ability to innovate and introduce new products, especially in response to emerging health needs, further contributes to its earnings.

QuidelOrtho Financial Statement Overview

Summary

QuidelOrtho faces significant financial challenges, with declining revenues, negative profitability, and fluctuating cash flows. While the balance sheet shows balanced leverage, the negative return on equity and operational inefficiencies are concerning. The company needs to address its revenue decline and improve operational efficiency to stabilize its financial position.

Income Statement

QuidelOrtho's income statement shows significant challenges, with declining revenue and negative profit margins. The TTM data reveals a substantial revenue drop of 76.7% and a negative net profit margin of -17.0%. Historical data indicates a consistent decline in revenue growth and profitability, with EBIT and EBITDA margins turning negative in recent periods. These trends highlight operational inefficiencies and market challenges.

Balance Sheet

The balance sheet reflects a stable debt-to-equity ratio of 1.0 in the TTM period, indicating balanced leverage. However, the return on equity is negative, suggesting inefficiencies in generating returns from equity. The equity ratio remains reasonable, but the declining equity and increasing debt levels pose potential risks to financial stability.

Cash Flow

Cash flow analysis shows improvement in free cash flow growth in the TTM period, with a significant increase of 305.6%. The operating cash flow to net income ratio is positive, indicating some operational cash generation despite net losses. However, historical fluctuations in free cash flow and negative free cash flow in previous periods highlight volatility in cash management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2021	Dec 2020	Dec 2019
Income Statement
Total Revenue	2.74B	2.78B	3.00B	1.70B	1.66B	534.89M
Gross Profit	1.25B	1.29B	1.49B	1.28B	1.35B	320.81M
EBITDA	222.70M	-1.46B	607.00M	955.44M	1.09B	143.76M
Net Income	-466.40M	-2.05B	-10.10M	704.20M	810.29M	72.92M
Balance Sheet
Total Assets	6.38B	6.42B	8.56B	2.43B	1.87B	910.87M
Cash, Cash Equivalents and Short-Term Investments	151.70M	98.30M	167.30M	828.50M	489.94M	52.77M
Total Debt	2.79B	2.68B	2.61B	139.30M	108.50M	112.30M
Total Liabilities	3.59B	3.44B	3.56B	501.00M	538.46M	351.05M
Stockholders Equity	2.79B	2.98B	5.01B	1.93B	1.33B	559.82M
Cash Flow
Free Cash Flow	123.30M	-112.10M	70.90M	513.14M	564.84M	107.26M
Operating Cash Flow	200.40M	83.00M	280.20M	805.87M	629.76M	134.49M
Investing Cash Flow	-183.60M	-149.90M	-187.60M	-319.53M	-63.32M	-27.23M
Financing Cash Flow	25.70M	48.80M	-265.80M	-173.18M	-130.28M	-98.28M

QuidelOrtho Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 29.80
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QDEL, the sentiment is Positive. The current price of 29.8 is above the 20-day moving average (MA) of 28.71, above the 50-day MA of 28.18, and below the 200-day MA of 31.89, indicating a neutral trend. The MACD of 0.26 indicates Negative momentum. The RSI at 57.37 is Neutral, neither overbought nor oversold. The STOCH value of 89.81 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for QDEL.

QuidelOrtho Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HOLX	69 Neutral	$16.45B	30.67	11.38%	―	1.28%	-17.73%
HAE	68 Neutral	$2.47B	15.67	18.27%	―	0.91%	45.81%
MASI	56 Neutral	$8.00B	―	-20.54%	―	-8.36%	-669.36%
BAX	54 Neutral	$11.78B	―	-3.30%	2.96%	-27.41%	67.01%
QDEL	52 Neutral	$2.02B	-4.56	-14.80%	―	-3.00%	76.48%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
STAA	50 Neutral	$1.23B	―	-25.55%	―	-32.59%	-667.81%

QuidelOrtho Corporate Events

QuidelOrtho Completes Major Debt Refinancing Transaction

On August 21, 2025, QuidelOrtho Corporation completed a significant debt refinancing transaction, entering into a Credit Agreement with Bank of America and other lenders. This agreement includes a $1.15 billion senior secured term loan A, a $100 million delayed draw term loan A, a $1.45 billion senior secured term loan B, and a $700 million revolving credit facility. The refinancing allows QuidelOrtho to extend its debt maturities, reduce required amortization payments, and improve financial flexibility, supporting future growth and strengthening its capital structure.

The most recent analyst rating on (QDEL) stock is a Hold with a $26.00 price target. To see the full list of analyst forecasts on QuidelOrtho stock, see the QDEL Stock Forecast page.

QuidelOrtho’s Earnings Call: Mixed Sentiment with Global Growth

QuidelOrtho Corporation’s recent earnings call presented a mixed sentiment, highlighting both achievements and challenges. While the company celebrated international growth and profitability improvements, it faced hurdles in North American revenue and a decline in COVID-related income. Cost-saving measures and improved margins were positive notes, but caution was advised due to revised COVID revenue guidance and challenges in China.

QuidelOrtho Reports Q2 2025 Financial Results

QuidelOrtho Corporation is a global leader in in vitro diagnostics, specializing in innovative diagnostic technologies for point-of-care settings, clinical labs, and transfusion medicine. The company is known for its expertise in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, providing fast and reliable diagnostics worldwide.